UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 144

Sortiert nach

CH5424802, a Selective ALK Inhibitor Capable of Blocking the Resistant Gatekeeper Mutant

Cancer cell, 2011-05, Vol.19 (5), p.679-690

2011

Link zum Volltext

Verfügbarkeit prüfen

Disruption of CRAF-Mediated MEK Activation Is Required for Effective MEK Inhibition in KRAS Mutant Tumors

Cancer cell, 2014-05, Vol.25 (5), p.697-710

2014

Link zum Volltext

Verfügbarkeit prüfen

Mechanism of Oncogenic Signal Activation by the Novel Fusion Kinase FGFR3-BAIAP2L1

Molecular cancer therapeutics, 2015-03, Vol.14 (3), p.704-712

2015

Link zum Volltext

Verfügbarkeit prüfen

Inhibition of metastasis of rhabdomyosarcoma by a novel neutralizing antibody to CXC chemokine receptor‐4

Cancer science, 2014-10, Vol.105 (10), p.1343-1350

2014

Link zum Volltext

Verfügbarkeit prüfen

ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor

Molecular cancer therapeutics, 2015-12, Vol.14 (12), p.2831-2839

2015

Link zum Volltext

Verfügbarkeit prüfen

Indoleamine 2,3-Dioxygenase Serves as a Marker of Poor Prognosis in Gene Expression Profiles of Serous Ovarian Cancer Cells

Clinical cancer research, 2005-08, Vol.11 (16), p.6030-6039

2005

Link zum Volltext

Verfügbarkeit prüfen

Inhibition of lymphatic metastasis in neuroblastoma by a novel neutralizing antibody to vascular endothelial growth factor‐D

Cancer science, 2012-12, Vol.103 (12), p.2144-2152

2012

Link zum Volltext

Verfügbarkeit prüfen

Enhanced antitumor activity of erlotinib in combination with the Hsp90 inhibitor CH5164840 against non‐small‐cell lung cancer

Cancer science, 2013-10, Vol.104 (10), p.1346-1352

2013

Link zum Volltext

Verfügbarkeit prüfen

A signature-based method for indexing cell cycle phase distribution from microarray profiles

BMC genomics, 2009-03, Vol.10 (1), p.137-137

2009

Link zum Volltext

Verfügbarkeit prüfen

Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)‐overexpressing cancers

Cancer science, 2012-02, Vol.103 (2), p.342-349

2012

Link zum Volltext

Verfügbarkeit prüfen

Synthesis and structure–activity relationships of novel benzofuran farnesyltransferase inhibitors

Bioorganic & medicinal chemistry letters, 2009-03, Vol.19 (6), p.1753-1757

2009

Link zum Volltext

Verfügbarkeit prüfen

The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of CH4987655 in Healthy Volunteers: Target Suppression Using a Biomarker

Clinical cancer research, 2009-12, Vol.15 (23), p.7368-7374

2009

Link zum Volltext

Verfügbarkeit prüfen

The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor

Molecular cancer therapeutics, 2014-11, Vol.13 (11), p.2547-2558

2014

Link zum Volltext

Verfügbarkeit prüfen

A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations

Clinical cancer research, 2019-05, Vol.25 (9), p.2699-2707

2019

Link zum Volltext

Verfügbarkeit prüfen

YES1 Is a Targetable Oncogene in Cancers Harboring YES1 Gene Amplification

Cancer research (Chicago, Ill.), 2019-11, Vol.79 (22), p.5734-5745

2019

Link zum Volltext

Verfügbarkeit prüfen

Sustained ERK inhibition maximizes responses of BrafV600E thyroid cancers to radioiodine

The Journal of clinical investigation, 2016-11, Vol.126 (11), p.4119-4124

2016

Link zum Volltext

Verfügbarkeit prüfen

Progress of research and development of MAPK pathway inhibitors

Folia Pharmacologica Japonica, 2013, Vol.141(1), pp.15-21

Ishii, Nobuya

2013

Link zum Volltext

Verfügbarkeit prüfen

Enhanced Inhibition of ERK Signaling by a Novel Allosteric MEK Inhibitor, CH5126766, That Suppresses Feedback Reactivation of RAF Activity

Cancer research (Chicago, Ill.), 2013-07, Vol.73 (13), p.4050-4060

2013

Link zum Volltext

Verfügbarkeit prüfen

Acquired JHDM1D-BRAF Fusion Confers Resistance to FGFR Inhibition in FGFR2 -Amplified Gastric Cancer

Molecular cancer therapeutics, 2018-10, Vol.17 (10), p.2217-2225

2018

Link zum Volltext

Verfügbarkeit prüfen

Discovery of [5-Amino-1-(2-methyl‑3H‑benzimidazol-5-yl)pyrazol-4-yl]-(1H‑indol-2-yl)methanone (CH5183284/Debio 1347), An Orally Available and Selective Fibroblast Growth Factor Receptor (FGFR) Inhibitor

Journal of medicinal chemistry, 2016-12, Vol.59 (23), p.10586-10600

2016

Link zum Volltext

Verfügbarkeit prüfen

The Selective Class I PI3K Inhibitor CH5132799 Targets Human Cancers Harboring Oncogenic PIK3CA Mutations

Clinical cancer research, 2011-05, Vol.17 (10), p.3272-3281

2011

Link zum Volltext

Verfügbarkeit prüfen

Abstract 4881: Molecular screening of patients with FGFR alterations for phase 1 (ph1) study with the selective FGFR inhibitor Debio 1347

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.4881-4881

2019

Link zum Volltext

Verfügbarkeit prüfen

Abstract 123: Mechanism of oncogenic signal activation by the novel fusion kinase FGFR3-BAIAP2L1

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.123-123

2015

Link zum Volltext

Verfügbarkeit prüfen

Abstract 3028: ERK signal suppression and sensitivity to CH5183284/Debio 1347, a selective FGFR inhibitor

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.3028-3028

2016

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 144

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(132)
Mit Volltextzugriff
(132)

Publikationsform

Sprache

Englisch
(134)
Japanisch
(40)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

CH5424802, a Selective ALK Inhibitor Capable of Blocking the Resistant Gatekeeper Mutant

Disruption of CRAF-Mediated MEK Activation Is Required for Effective MEK Inhibition in KRAS Mutant Tumors

Mechanism of Oncogenic Signal Activation by the Novel Fusion Kinase FGFR3-BAIAP2L1

Inhibition of metastasis of rhabdomyosarcoma by a novel neutralizing antibody to CXC chemokine receptor‐4

ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor

Indoleamine 2,3-Dioxygenase Serves as a Marker of Poor Prognosis in Gene Expression Profiles of Serous Ovarian Cancer Cells

Inhibition of lymphatic metastasis in neuroblastoma by a novel neutralizing antibody to vascular endothelial growth factor‐D

Somatic copy number alterations associated with Japanese or endometriosis in ovarian clear cell adenocarcinoma

Enhanced antitumor activity of erlotinib in combination with the Hsp90 inhibitor CH5164840 against non‐small‐cell lung cancer

A signature-based method for indexing cell cycle phase distribution from microarray profiles

Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)‐overexpressing cancers

Synthesis and structure–activity relationships of novel benzofuran farnesyltransferase inhibitors

The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of CH4987655 in Healthy Volunteers: Target Suppression Using a Biomarker

The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor

A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations

YES1 Is a Targetable Oncogene in Cancers Harboring YES1 Gene Amplification

Sustained ERK inhibition maximizes responses of BrafV600E thyroid cancers to radioiodine

Progress of research and development of MAPK pathway inhibitors

Enhanced Inhibition of ERK Signaling by a Novel Allosteric MEK Inhibitor, CH5126766, That Suppresses Feedback Reactivation of RAF Activity

Acquired JHDM1D-BRAF Fusion Confers Resistance to FGFR Inhibition in FGFR2 -Amplified Gastric Cancer

Discovery of [5-Amino-1-(2-methyl‑3H‑benzimidazol-5-yl)pyrazol-4-yl]-(1H‑indol-2-yl)methanone (CH5183284/Debio 1347), An Orally Available and Selective Fibroblast Growth Factor Receptor (FGFR) Inhibitor

The Selective Class I PI3K Inhibitor CH5132799 Targets Human Cancers Harboring Oncogenic PIK3CA Mutations

Abstract 4881: Molecular screening of patients with FGFR alterations for phase 1 (ph1) study with the selective FGFR inhibitor Debio 1347

Abstract 123: Mechanism of oncogenic signal activation by the novel fusion kinase FGFR3-BAIAP2L1

Abstract 3028: ERK signal suppression and sensitivity to CH5183284/Debio 1347, a selective FGFR inhibitor

Suchergebnisse filtern